Drug companies rapped for anticompetitive behaviour


The Italian health ministry is following up on rulings from the country’s competition authorities and demanding billions of euros in damages resulting from anticompetitive behaviour.

The charges relate to Roche and Novartis’s alleged restriction of competition between two related antibody drugs that the two firms co-promote. Lucentis (ranibizumab) and Avastin (bevacizumab) are derived from the same monoclonal antibody that inhibits blood vessel growth.

Avastin is approved for treating certain cancers, whereas Lucentis is used to treat vision loss caused by age-related wet macular degeneration (AMD). But since Avastin is much cheaper, doctors have tended to try and use it off-label to treat AMD. The Italian authorities claim the companies made an agreement to block sales of Avastin in favour of Lucentis, and have asked for €1.2 billion (£977 million) in damages covering 2012–2014. The companies have denied any wrongdoing.

In the same action, the ministry is seeking damages from Pfizer for allegedly abusing its market monopoly position regarding the eye drug Xatalan (latanoprost), by preventing eligible generic versions from entering the market.


Related Content

Roche rapped for side-effect reporting failure

26 June 2012 Business

news image

European medicines regulator names and shames Swiss giant for not disclosing 80,000 instances of potential adverse drug react...

Riding new waves

6 January 2015 Business

news image

Pharmaceutical industry roundup of 2014

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent